To improve HER2-positive breast cancer patients’ health outcomes and health-related quality of life, the government, policymakers, and other relevant parties (especially in low- and middle-income countries) should have practical policies and solutions to support patients in their long-term treatment period. The gene discussed is ERBB2; the disease is breast carcinoma.